You are here

Signet Laboratories Releases DJ-1 Predictive Diagnostic for Parkinson’s Disease

DEDHAM, Mass., July 9 /PRNewswire/ -- In a new contribution to the fight against Parkinson's Disease, Signet Laboratories, Inc., a pioneer in evidence- based medicine (EviMed), today announced the release of its DJ-1 monoclonal antibody, which is a potential diagnostic for predicting the emergence of the disease.

"Parkinson's Disease currently affects over a half-million people in the U.S. alone, with 50,000 new cases diagnosed each year," said Dr. Richard D. Gill, President and CEO of Signet. "Unfortunately, Parkinson's is a very difficult disease to detect, and neurologists must rely on an evaluation of symptoms, followed by administration of anti-Parkinson's drugs to see if the patient responds. This is a long and difficult process, and sometimes leads to incorrect diagnoses that prevent a patient's effective treatment."

The DJ-1 protein has been recently identified as causative of early-onset, autosomal recessive Parkinson's Disease. Signet has developed a monoclonal antibody for detecting DJ-1, to map the protein in regions of the brain associated with the incidence of Parkinson's. DJ-1 could prospectively provide an accurate testing regime for diagnosing the elusive disorder.

About Signet Laboratories, Inc.

Signet Laboratories, Inc. is a pioneering evidence-based medicine (EviMed) company that is committed to developing and commercializing predictive diagnostics and preventive drugs and therapies for critical disease states.

Evidence-based medicine is the treatment of diseases prior to their full manifestation, with the goal of reducing their occurrence and preventing disease progression by early identification of patients with increased risk factors.

Drawing on long experience in developing diagnostic assays and antibodies for disease detection and treatment, Signet's mission is to create novel diagnostics and drugs for patients at risk for cancer, sepsis and renal failure (SARF), neurodegenerative diseases including Alzheimer's, Parkinson's and Huntington's, and prion diseases such as "Mad Cow" and vCJD.

In addition to diagnostics, drugs and therapies, Signet offers a complete product line of over 800 manufactured antibodies, ELISA kits, detection products and accessories in an FDA registered facility. Signet products are available online, at http://www.signetlabs.com/. For more information, contact Terri Daly at (781) 915-1404, or via email: tdaly@signetlabs.com.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function